Drug profile · INN
pamidronate disodium
PAMISOL
pamidronate disodium (PAMISOL) is a farnesyl diphosphate synthase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — pamidronate disodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
pamidronate disodium (PAMISOL) is a farnesyl diphosphate synthase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Farnesyl diphosphate synthase inhibitor
Primary target: Farnesyl pyrophosphate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pamidronate disodium?
pamidronate disodium (PAMISOL) is a farnesyl diphosphate synthase inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pamidronate disodium?
PAMISOL is a marketed brand name for pamidronate disodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pamidronate disodium?
pamidronate disodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.